Zensun Obtained the Exciting Results of US Phase II Clinical Trial
2013-02-21
On Dec. 20th, 2012, Zensun finished patient recruitment for US Phase II clinical trial of anti-heart failure drug—rhNRG-1. On Feb 20th, Zensun unblinded the clinical data which showed an excellent consistency with Chinese Phase II clinical results. It means the successful Chinese clinical results of rhNRG-1 have been confirmed by US clinical trial. And it is a solid step for Zensun to put this innovative drug on global pharmaceutical market.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to
